A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population
This study predicted that infant immunization with PCV20 was the most cost-effective option compared with PCV13 and PCV15. These results could help decision-makers implement the optimal PCV strategy in the French pediatric NIP.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- S. Fiévez (ORCID: https://orcid.org/0009-0009-8013-2399)
- Ayman Sabra (ORCID: https://orcid.org/0000-0001-7971-4652)
- Marine Sivignon
- L. Bellier
- Maud Beillat (ORCID: https://orcid.org/0009-0004-2825-1394)
- An Ta (ORCID: https://orcid.org/0000-0003-0929-6365)
- Emmanuelle Blanc
- J. Khoury
- Aleksandar Ilic
Institutions
- Pfizer (United Kingdom) (GB)
- Pfizer (France) (FR)
- Pfizer (Canada) (CA)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1007/s40121-025-01209-z
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Pfizer